One- and Two-Year Outcomes of Switching to a Dolutegravir-Based ART Regimen: An Observational Emulation of Sequential Target Trials
Amy Zheng, Eleanor J Murray, Alana T Brennan, Ross Greener, Emma M Kileel, Jacob Bor, Willem D F Venter, Pedro T Pisa, Matthew P Fox, Mhairi Maskew · 2026
Read One- and Two-Year Outcomes of Switching to a Dolutegravir-Based ART Regimen: An Observational Emulation of Sequential Target Trials by Amy Zheng, Eleanor J Murray, Alana T Brennan, Ross Greener, Emma M Kileel, Jacob Bor, Willem D F Venter, Pedro T Pisa, Matthew P Fox, Mhairi Maskew (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13132165.txt.
Description
Zheng and coauthors weigh gains from a switch to a newer HIV drug. Trials of the switch left out patients with poor virus control. In real clinics, doctors switch such patients all the same. The team mimicked a trial with real clinic records.
Records came from a large HIV clinic in Johannesburg, South Africa. Patients were on the older drug at each trial start. All were aged 16 or more and not pregnant. The team tracked stay in care and virus control at one and two years. Their method aims to give fair, trial-like answers from real data.
Catalog record
| CREATOR | Amy Zheng, Eleanor J Murray, Alana T Brennan, Ross Greener, Emma M Kileel, Jacob Bor, Willem D F Venter, Pedro T Pisa, Matthew P Fox, Mhairi Maskew |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |